Name: Fadraciclib (CYC065)
Brand: Selleck Chemicals
SKU: S7371
Availability: InStock
Rating: 5 (2 reviews)

Jump to

Quality Control

Batch: S737101 DMSO]80 mg/mL]false]Ethanol]80 mg/mL]false]Water]Insoluble]false Purity: 99.88%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS/MSDS
Datasheet

99.88

Related Targets	HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase Casein Kinase
Other CDK Inhibitors	AS2863619 Ro-3306 SEL120 (SEL120-34A) hydrochloride INX-315 Tagtociclib (PF-07104091) PF-07220060 (CDK4/6-IN-6) AZD4573 ON123300 Enitociclib (BAY 1251152) Samuraciclib (ICEC0942) hydrochloride

Solubility

In vitro
Batch:

DMSO : 80 mg/mL (201.24 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 80 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.000mg/ml (10.06mM)	Taking the 1 mL working solution as an example, add 50 μL of 80 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.000mg/ml (5.03mM)	Taking the 1 mL working solution as an example, add 50 μL of 40 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	397.52	Formula	C₂₁H₃₁N₇O	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1070790-89-4	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	CCC(NC1=NC(=C2N=C[N](C(C)C)C2=N1)NCC3=C(C)C=C(C)N=C3)C(C)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	CDK2 5 nM CDK9 26 nM
In vitro	Fadraciclib effectively downregulates pro-survival and leukemogenic proteins and that short pulse treatment is sufficient to substantially decrease cell viability of the majority of AML cell lines tested via apoptotic induction.<sup><a class="sref" href="#s_ref">[1]</a></sup>
In vivo	Fadraciclib shows potent anti-leukemic activity in two subcutaneous xenograft models EOL-1 (with MLL-PTD) and HL60 (non MLLr/MLL-PTD AML with MYC amplification).<sup><a class="sref" href="#s_ref">[1]</a></sup>
References	[1] https://pubmed.ncbi.nlm.nih.gov/32645016/ [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192769/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-10)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02813135	RECRUITING	Pediatric Cancer	Gustave Roussy, Cancer Campus, Grand Paris	2016-08-03	PHASE1; PHASE2
NCT04983810	UNKNOWN	Solid Tumor, Adult; Lymphoma	Cyclacel Pharmaceuticals, Inc.	2021-07-12	PHASE1; PHASE2
NCT05168904	SUSPENDED	Leukemia; Myelodysplastic Syndrome(MDS)	Cyclacel Pharmaceuticals, Inc.	2021-10-22	PHASE1; PHASE2
NCT05817890	COMPLETED	Healthy	Cyclacel Pharmaceuticals, Inc.	2023-03-03	EARLY_PHASE1
NCT05817890	Active not recruiting	Healthy	Cyclacel Pharmaceuticals Inc.	2023-03-03	Early Phase 1
NCT04017546	COMPLETED	AML; MDS	Cyclacel Pharmaceuticals, Inc.	2019-08-02	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Fadraciclib (CYC065) CDK inhibitor

Chemical Structure

Molecular Weight: 397.52